ArticleInternational journal of clinical and experimental pathology2026
A study on the diagnostic value of PAX1 methylation gene testing in cervical lesions with incomplete visibility of the squamocolumnar junction.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effectiveness of PAX1 methylation gene testing in cervical lesions where the squamocolumnar junction (SCJ) is incompletely visible.
methodsFor patients with TCT ≥ ASCUS or HR-HPV positivity, whose colposcopy results indicate incomplete visibility of the SCJ, cervical exfoliated cells were collected for PAX1 gene methylation testing. Using histopathology results as the gold standard, the study calculated the positive rate of PAX1 methylation testing across various lesion grades, assessing the sensitivity, specificity, positive predictive value, negative predictive value, and positive concordance rate with histopathology for high-grade cervical lesions.
resultsThe PAX1 positivity rates in the cervicitis, LSIL, HSIL, and CC groups were 30% (3/10), 30.43% (7/23), 51.28% (20/39), and 71.42% (5/7), respectively. The positivity rate in the LSIL group (cervicitis and LSIL), at 29.72% (11/37), was significantly lower than in the HSIL+ group (HSIL and CC), which was 54.76% (23/42) (P < 0.05). For HSIL+ lesions, PAX1 methylation testing showed a sensitivity of 54.76%, specificity of 70.27%, positive predictive value of 67.65%, negative predictive value of 57.78%, positive likelihood ratio of 1.84, and negative likelihood ratio of 0.22. In comparison, HPV testing for HSIL+ showed a sensitivity of 100% and specificity of 13.51%; TCT testing for HSIL+ had a sensitivity of 35.71% and specificity of 94.59%. The positive concordance rate with histopathology was 97.1% for the PAX1 group, 95.9% for the high-risk HPV group, and 100% for the TCT group.
conclusionThe overall efficacy of PAX1 in diagnosing high-grade cervical lesions is relatively high, enhancing diagnostic accuracy to a certain extent and making it suitable for further clinical application and promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.